[EQ] Testing Times in Russia: How to facilitate access to essential drugs and get more value out of pharmaceutical expenditures?

Testing Times in Russia:
How to facilitate access to essential drugs and get more value out of pharmaceutical expenditures?

 

The World Bank in Russia - Russian Economic Report
From Crisis to Recovery – June 2009

 

Available online as PDF file [30p] – see page 16 at:

http://siteresources.worldbank.org/INTRUSSIANFEDERATION/Resources/305499-1245838520910/rer19-eng.pdf

 

Website: http://go.worldbank.org/Z61KG4EK20

 

“…..This chapter assesses how the current economic downturn is affecting drug prices and the affordability of medicines, particularly among vulnerable population groups. A related question concerns possible measures that could be adopted in Russia to facilitate access to essential drugs and ensure rational drug use. The chapter focuses on special issues of affordability and access.

 

It also suggests the need for assessing the regulatory role of government in different areas of the pharmaceutical market. Such an assessment would provide policymakers, insurance providers, and healthcare institutions with an analysis of regulation’s impact on efficiency, quality, equity, and cost control….”

 

This chapter was prepared by Patricio V. Marquez, Lead Health Specialist, Europe and Central Asia, World Bank, and Mikhail Bonch-Osmolovskiy, Economist, ECSPE, World Bank, in consultation and with the advice from the following international pharmaceutical specialists: Albert Figueras, Catalan Pharmacological Institute, Barcelona, Spain; Rob Verhage and Wilbert Bannenberg, Health Research for Action (HERA), Suriname and the Netherlands; Martin Auton, Health Action International (HAI), Amsterdam, the Netherlands; Kalipso Chalkidou, National Institute of Health and Clinical Excellence (NICE), London, England; as well as Igor Sheiman, Professor of Health Economics, Higher School of Economics, Moscow, Russia. Additional comments were provided by Andrei Markov, Senior Human Development Specialist; Salman Zaidi, Senior Economist, ECSPE; Willy de Geynd, Lead Health Specialist (ret.); and Sevil Kamalovna Salakhutdinova, Health Specialist, World Bank

 

 *      *     *

This message from the Pan American Health Organization, PAHO/WHO, is part of an effort to disseminate
information Related to: Equity; Health inequality; Socioeconomic inequality in health; Socioeconomic
health differentials; Gender; Violence; Poverty; Health Economics; Health Legislation; Ethnicity; Ethics;
Information Technology - Virtual libraries; Research & Science issues.  [DD/ KMS Area]

“Materials provided in this electronic list are provided "as is". Unless expressly stated otherwise, the findings
and interpretations included in the Materials are those of the authors and not necessarily of The Pan American
Health Organization PAHO/WHO or its country members”.
------------------------------------------------------------------------------------
PAHO/WHO Website

Follow us on Twitter: http://twitter.com/eqpaho

Equity List - Archives - Join/remove: http://listserv.paho.org/Archives/equidad.html

 

 

    IMPORTANT: This transmission is for use by the intended recipient and it may contain privileged, proprietary or confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please notify us immediately by email to infosec@paho.org, and please dispose of and delete this transmission. Thank you.